Key result
Experimental inactivated poliovirus vaccine based on Sabin strains (s-IPV) showed comparable immunogenicity and basic characteristics to commercial IPV prepared from wild strains in animal models.
Experimental s-IPV demonstrates comparable immunogenicity and basic characteristics to commercial IPV in animal models.
Hypothesis-generating for s-IPV development; human trials needed to confirm immunogenicity and safety.
The results of development of experimental series of inactivated poliovirus vaccine based on Sabin strains (s-IPV) using conventional modern techniques are presented. Comparative analysis of immunogenicity of the experimental s-IPV and commercial IPV prepared from «wild» poliovirus strains (Imovax, Sanofi Pasteur S.A., France) using several models of laboratory animals showed their identity regarding Sabin and «wild» strains. Original method (an ELISA using specific chicken egg yolk antibodies of class Y-IgY) for quantitative determination of D-antigen in elaboration of vaccine formulation has been developed and protected by patent; conventional control methods in accordance with the WHO and European Pharmacopoeia requirements have been adopted. Finally, at experimental level it was shown that basic characteristics of the s-IPV are comparable with those of commercial IPV prepared from «wild» poliovirus strains
No takes yet. Share an insight, caveat, or question.
Ap et al. (2016) studied Poliovirus vaccination. Experimental inactivated poliovirus vaccine based on Sabin strains (s-IPV) vs. Commercial IPV prepared from wild poliovirus strains (Imovax) was evaluated on Immunogenicity and basic characteristics. Experimental inactivated poliovirus vaccine based on Sabin strains (s-IPV) showed comparable immunogenicity and basic characteristics to commercial IPV prepared from wild strains in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: